Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134080 · ClinicalTrials.gov registry record · Phase 1
FAAH Inhibitor Trial for Adults With Tourette Syndrome
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02134080 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 5 participants.
The verdict
NCT02134080, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this trial is to examine the safety, tolerability and feasibility in the use of a FAAH inhibitor for the treatment of adults with Tourette syndrome.
Interventions
- DRUG Placebo
- DRUG PF-04457845
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02134080
The ClinicalTrials.gov registry entry for NCT02134080 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02134080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02134080 about?
NCT02134080 is a clinical study titled "FAAH Inhibitor Trial for Adults With Tourette Syndrome". The purpose of this trial is to examine the safety, tolerability and feasibility in the use of a FAAH inhibitor for the treatment of adults with Tourette syndrome.
What is the current status of trial NCT02134080?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2014-05. Estimated completion is 2017-03.
What interventions are being tested in trial NCT02134080?
The interventions under investigation include: Placebo (DRUG), PF-04457845 (DRUG).
Who is sponsoring clinical trial NCT02134080?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.